Apple's health ambitions have long been framed as a wellness feature, but a closer look at recent insurance reimbursement codes, FDA clearances, and hospital pilot programs reveals a deliberate revenue strategy. Lucas and Luna unpack how the Apple Watch's atrial fibrillation detection, sleep apnea alerts, and the new continuous glucose monitoring patent filings signal a shift from consumer gadget to regulated medical device play. They examine why insurance companies are starting to subsidize the Watch, how the Health app's integration with Epic Systems gives Apple a data moat, and what this means for competitors like Dexcom and Abbott. A specific number: Apple's health-related services revenue is estimated to hit $6 billion this year, growing at 25% year-over-year. The hosts also discuss why this flywheel could make Apple the most important healthcare company of the next decade, and why regulators are paying close attention.